Planning Capital Management Corp Sells 824 Shares of Zoetis Inc. (NYSE:ZTS)

Planning Capital Management Corp decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 75.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 273 shares of the company’s stock after selling 824 shares during the period. Planning Capital Management Corp’s holdings in Zoetis were worth $53,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ZTS. Sarasin & Partners LLP increased its holdings in Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after purchasing an additional 1,904,899 shares during the last quarter. Swedbank AB bought a new stake in shares of Zoetis in the 1st quarter valued at $210,815,000. International Assets Investment Management LLC lifted its holdings in Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after acquiring an additional 937,700 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Zoetis by 7,608.6% in the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after acquiring an additional 824,843 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Zoetis by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after purchasing an additional 414,605 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 1.4 %

Zoetis stock opened at $174.63 on Friday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a market capitalization of $78.79 billion, a PE ratio of 32.83, a P/E/G ratio of 2.72 and a beta of 0.90. The company’s 50-day moving average is $187.61 and its 200-day moving average is $180.02. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the company earned $1.36 earnings per share. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Sell-side analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several research reports. JPMorgan Chase & Co. upped their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. BTIG Research increased their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus boosted their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.